RetinAI highlights Geographic Atrophy research with models available for analysis to enable the right decision sooner during clinical studies

Bern, Switzerland, April 21, 2022 - RetinAI Medical AG (“RetinAI”) is pleased to share research findings from three published papers in Geographic Atrophy (GA). In collaboration with the Department of Ophthalmology at the University of Lausanne, Jules-Gonin Hospital, researchers at RetinAI developed a model for predicting atrophy risk in patients with non-exudative age-related macular degeneration (AMD)[1].

One-hundred and twenty-nine (129) eyes were analyzed to create a model for predicting atrophy progression using OCT scans from treatment-naive patients. The model demonstrated performance for predicting future progression, evaluating data from baseline visits and the preceding visit to calculate atrophy risk up to 7 years in some cases. A patient-specific atrophy risk map was computed using this model for RORA progression based on a novel continuous-time output, strengthening the model’s performance to predict future atrophy. Other models developed by the researchers in GA include automated atrophy segmentation of retinal pigment epithelium and outer retinal atrophy (RORA)[2] and automated foveal detection in GA from OCT imaging[3].

RetinAI partners with experts in ophthalmology to help accelerate their data analysis and more effectively carry out target-based research for improved study design and clinical research. RetinAI’s models in GA provide companies with research tools they can use to analyze datasets at-scale and gain a deep understanding on biomarker profiles and patient subgroups based on disease progression or outcomes. For RetinAI’s solutions for pharma and life sciences, please visit:

About RetinAI

RetinAI Medical AG (RetinAI), founded in early 2017, is a Swiss company developing software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. The company builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team combines clinical, technical, and scientific knowledge to foster the transition from reactive to preventive medicine for severe diseases affecting the eye.

[1] Personalized Atrophy Risk Mapping in Age-Related Macular Degeneration published in Translational Vision Science & Technology, November 2021

[2] Fully-automated atrophy segmentation in dry age-related macular degeneration in optical coherence tomography published in Nature Scientific Reports, November 2021

[3] Automated foveal location detection on spectral-domain optical coherence tomography in geographic atrophy patients published in Graefe’s Archive for Clinical and Experimental Ophthalmology, January 2022